


Supplementary material to "Assessing the evolving impact of the COVID-19 pandemic in chronic dialysis recipients along the wave subperiods and vaccination rollout: a French national study" by Leye E et al.



Supplementary Figure S1: Kidney transplantation events among CDR in France in years 2015 to 2022.

Prepandemic years (years 2015 to 2019) were pooled, and dark green solid line indicates the cumulative mean value observed each month considering the 5 corresponding years, while the light green area delineates the minimum and maximum observed range.

Supplementary Table S1. Multivariable analysis of mortality in the 71,583 chronic dialysis patients and 143,166 matched controls during the prepandemic and pandemic periods.

Variable	Variable value	Deaths observed (n) / person-years (n)	HR [95% CI]	p value
Period	Prepandemic	25,353 / 330,116	1 (reference)	
	Pandemic	25,319 / 309225	1.03 [1.00–1.06]	0.02
Population	Matched-control individuals	22,285 / 454,432	1 (reference)	
	CDR	28,387 / 184,909	3.15 [3.07–3.23]	<0.01
interaction	Period × population		1.02 [0.98–1.05]	0.34

Abbreviations used: CI, confidence interval; HR, hazard ratio.

Supplementary Table S2. Multivariable analysis of kidney transplantation events in the 71,583 chronic dialysis recipients of the study during the prepandemic and pandemic periods (Fine and Gray models).

Model	Variable	Kidney transplantations (n) / person-years (n)	SHR [95% CI]	p value
Model S1	Prepandemic period	5,853 / 98,444	1 (reference)	
	Pandemic period	4,172 / 86,465	0.80 [0.77–0.83]	<0.01
Model S2	Prepandemic period	5,853 / 98,444	1 (reference)	
	Pandemic period, no history of COVID-19-related hospitalization	4,060 / 82,804	0.81 [0.78–0.85]	<0.01
	Pandemic period, ≥1 COVID-19-related hospitalization	112 / 3,661	0.56 [0.47–0.68]	<0.01
Model S3	Prepandemic period	5,853 / 98,444	1 (reference)	
	1 st wave	67 / 6,837	0.17 [0.13–0.21]	<0.01
	1 st interwave	505 / 9,892	0.88 [0.81–0.97]	<0.01
	2 nd wave	1,024 / 21,604	0.79 [0.74–0.85]	<0.01
	2 nd interwave	874 / 17,503	0.84 [0.78–0.90]	<0.01
	3 rd wave	673 / 13,075	0.83 [0.77–0.90]	<0.01
	3 rd interwave	1,029 / 17,553	0.94 [0.88–1.00]	>0.01

All SHR shown correspond to Fine and Gray regression models also adjusted for the following covariates: sex, age category, diabetes, and cardiovascular disease. Abbreviations used: CI, confidence interval; SHR, subdistribution hazard ratio.

Supplementary Table S3. Multivariable analysis of mortality in the 71,583 chronic dialysis recipients and 143,166 matched-control individuals of the study during the prepandemic and pandemic periods (Fine and Gray models).

Model	Variable	Chronic dialysis recipients Deaths observed (n) / person-years (n)	SHR [95% CI]	p value	Matched-controls individuals Deaths observed (n) / person-years (n)	SHR [95% CI]	p value
Model S4	Prepandemic period	14,455 / 98,444	1 (reference)		10,898 / 231,672	1 (reference)	
	Pandemic period	13,932 / 86,465	1.14 [1.11–1.17]	<0.01	11,387 / 222,760	1.08 [1.05–1.11]	<0.01
Model S5	Prepandemic period	14,021 / 98,444	1 (reference)		10,898 / 231,672	1 (reference)	
	Pandemic period, no history of COVID-19-related hospitalization	11,924 / 82,804	1.03 [1.01–1.06]	0.01	10,110 / 220,149	0.99 [0.95–1.01]	0.31
	Pandemic period, ≥1 COVID-19- related hospitalization	2,008 / 3,661	3.56 [3.38–3.74]	<0.01	1,277 / 2,611	7.58 [7.11–8.08]	<0.01
Model S6	Prepandemic period	14,455 / 98,444	1 (reference)		10,898 / 231,672	1 (reference)	
	1 st wave	1,235 / 6,837	1.30 [1.22–1.37]	<0.01	1,036 / 17,386	1.27 [1.19–1.35]	<0.01
	1 st interwave	1,391 / 9,892	0.98 [0.92–1.03]	0.41	1,075 / 25,117	0.90 [0.84–0.95]	<0.01
	2 nd wave	3,860 / 21,604	1.26 [1.22–1.31]	<0.01	3,234 / 55,077	1.24 [1.19–1.29]	<0.01
	2 nd interwave	2,552 / 17,503	1.03 [0.98–1.07]	0.22	1,966 / 44,564	0.93 [0.89–0.98]	<0.01
	3 rd wave	2,208 / 13,075	1.18 [1.13–1.23]	<0.01	1,843 / 33,764	1.16 [1.10–1.22]	<0.01
	3 rd interwave	2,686 / 17,554	1.10 [1.05–1.14]	<0.01	2,233 / 46,852	1.00 [0.96–1.05]	0.93

All SHR shown correspond to Fine and Gray regression models also adjusted for the following covariates: sex, age category, diabetes, and cardiovascular disease. Abbreviations used: CI, confidence interval; SHR, subdistribution hazard ratio.

Supplementary Table S4. Multivariable analysis of COVID-19 hospitalization after a given number of vaccine doses received in the chronic dialysis recipients and matched-control individuals (Fine and Gray model).

Number of vaccine doses	Chronic dialysis recipients			Matched-controls individuals		
	Persons with a COVID-19 hospitalization (n) / person-years (n)	SHR [95% CI]	p value	Persons with a COVID-19 hospitalization (n) / person-years (n)	SHR [95% CI]	p value
0 or 1	3,006 / 39,494	1 (reference)		2,397 / 116,699	1 (reference)	
2 (vs. ≤ 1)	351 / 12,149	0.36 [0.32–0.41]	<0.01	264 / 42,935	0.29 [0.25–0.33]	<0.01
3 (1 st booster, vs. 2)	618 / 19,430	0.66 [0.58–0.76]	<0.01	486 / 49,045	0.68 [0.57–0.80]	<0.01
4 (2 nd booster, vs. 3)	396 / 6,915	0.76 [0.68–0.87]	<0.01	113 / 8,554	0.82 [0.65–1.03]	0.08

All SHR shown correspond to Fine and Gray regression models also adjusted for the following covariates: sex, age category, diabetes, cardiovascular disease, and waves and interwaves subperiods; they are reported per additional vaccine dose (i.e. 2 vs. ≤ 1, 3 vs. 2, and 4 vs. 3, respectively). Abbreviations used: CI, confidence interval; SHR, subdistribution hazard ratio.

Supplementary Table S5. Multivariable analysis of survival after a given number of vaccine doses received in the chronic dialysis recipients and matched-control individuals (Fine and Gray model).

Number of vaccine doses	Chronic dialysis recipients			Matched-controls individuals		
	Deaths observed (n) / person-years (n)	SHR [95% CI]	p value	Deaths observed (n) / person-years (n)	SHR [95% CI]	p value
0 or 1	7,137 / 41,084	1 (reference)		6,651 / 118,095	1 (reference)	
2 (vs. ≤ 1)	2,246 / 12,960	0.81 [0.77–0.86]	<0.01	1,949 / 43,567	0.65 [0.61–0.69]	<0.01
3 (1 st booster, vs. 2)	2,683 / 20,320	0.56 [0.53–0.60]	<0.01	2,174 / 49,501	0.61 [0.53–0.66]	<0.01
4 (2 nd booster, vs. 3)	1,638 / 10,548	0.88 [0.82–0.94]	<0.01	581 / 11,159	0.80 [0.73–0.89]	<0.01

All SHR shown correspond to Fine and Gray regression models also adjusted for the following covariates: sex, age category, diabetes, cardiovascular disease, and waves and interwaves subperiods; they are reported per additional vaccine dose (i.e. 2 vs. ≤ 1, 3 vs. 2, and 4 vs. 3, respectively). Abbreviations used: CI, confidence interval; SHR, subdistribution hazard ratio.